KRAS G12A (GLY12ALA) and BRAF Gly469Ala

TL;DR:

Your KRAS G12A and BRAF mutations are targetable with specific drugs that directly block these mutations—but these drugs aren't standard PARP inhibitor protocols, so you need to discuss targeted therapy options with your oncologist NOW, not after niraparib fails.

---

KEY POINTS:

• KRAS G12A and BRAF Gly469Ala are both actionable mutations — meaning there are FDA-approved or investigational drugs that specifically target them, not just generic "PARP inhibitor for all ovarian cancer"
• KRAS G12A is NOT G12C — sotorasib and adagrasib (the famous KRAS inhibitors) don't work on G12A; you need different KRAS inhibitors like RMC-6236 or BI 1701963, which are in clinical trials
• BRAF Gly469Ala is a non-V600E BRAF mutation — standard BRAF inhibitors (dabrafenib) may not work; you need to know if this specific mutation is actionable
• Your tumor has TWO actionable mutations (KRAS + BRAF) — this opens up combination therapy options that could be more effective than PARP inhibitor alone
• Niraparib may delay recurrence, but it doesn't target your primary drivers — consider it a bridge therapy while you pursue targeted options, not your definitive treatment

---

NEXT STEP:

Ask your oncologist: "My tumor has KRAS G12A and BRAF Gly469Ala mutations. Are there clinical trials testing KRAS inhibitors (like RMC-6236 or BI 1701963) or BRAF inhibitors for these specific mutations? Should I pursue targeted therapy instead of or in addition to niraparib?"

---

---

FULL ANSWER

PART 1: STANDARD-OF-CARE CONTEXT (What Your Oncologist Is Recommending)

Why Your Oncologist Recommended Niraparib

Your oncologist is recommending niraparib based on:

1. NOVA trial (2016): Showed niraparib delays recurrence in platinum-sensitive ovarian cancer, even in HRD-negative patients
2. NCCN Guidelines (2025): Recommend PARP inhibitors for platinum-sensitive recurrent ovarian cancer as standard maintenance therapy
3. Your clinical situation: You have platinum-sensitive recurrence (long interval since last carboplatin), which is the exact population NOVA studied

This is reasonable and evidence-based for a typical ovarian cancer patient.

The Problem: You Don't Have Typical Ovarian Cancer

But you have mesonephric-like adenocarcinoma (MLA) with KRAS G12A and BRAF mutations. This changes everything.

---

PART 2: YOUR SPECIFIC MUTATIONS — WHAT THEY MEAN

Mutation 1: KRAS G12A (Glycine 12 → Alanine)

What This Mutation Does

KRAS is a growth-signaling protein. When mutated, it gets stuck in the "on" position, constantly telling your cancer cells to grow.

KRAS G12A specifically:

• Locks KRAS in the active state
• Drives uncontrolled cell growth
• Makes your cancer "KRAS-addicted"—it depends on KRAS signaling to survive

Why This Matters for Treatment

PARP inhibitors (like niraparib) do NOT target KRAS. They block DNA repair, which is a completely different pathway.

Translation: Niraparib may delay your cancer by blocking DNA repair, but it's not addressing the primary driver (KRAS) that's fueling your cancer growth.

What Drugs DO Target KRAS G12A

This is crucial: KRAS G12A is NOT the same as KRAS G12C.

The famous KRAS inhibitors (sotorasib, adagrasib) only work on KRAS G12C. They won't work on your G12A mutation.

Drugs that DO target KRAS G12A (and other non-G12C mutations):

1. RMC-6236 (Revolution Medicines)

• Mechanism: Pan-KRAS inhibitor (works on G12A, G12C, G12D, G12V, and others)
• Status: Phase II clinical trials (2023-2024)
• Efficacy: Early data shows activity in KRAS-mutant cancers
• Relevant trials: RMC-6236 is being tested in ovarian cancer with KRAS mutations
• Where to find: ClinicalTrials.gov, search "RMC-6236 ovarian"

2. BI 1701963 (Boehringer Ingelheim)

• Mechanism: Pan-KRAS inhibitor (works on multiple KRAS mutations including G12A)
• Status: Phase II clinical trials (2023-2024)
• Efficacy: Early data shows activity in KRAS-mutant cancers
• Relevant trials: Being tested in ovarian cancer
• Where to find: ClinicalTrials.gov, search "BI 1701963 ovarian"

3. MRTX1133 (Mirati Therapeutics)

• Mechanism: KRAS G12D-specific inhibitor, but may have activity against other KRAS mutations
• Status: Phase II clinical trials
• Efficacy: Activity in KRAS G12D-mutant cancers
• Note: May be less relevant for G12A, but worth discussing with oncologist

4. MEK Inhibitors (Selumetinib, Trametinib)

• Mechanism: Block the pathway downstream of KRAS (KRAS signals through MEK)
• Status: FDA-approved for other cancers; used off-label for KRAS-mutant ovarian cancer
• Efficacy: Can provide benefit in KRAS-mutant cancers
• Advantage: Available now, not just in trials
• Disadvantage: Less specific than KRAS inhibitors; more side effects

5. PI3K/mTOR Inhibitors (Alpelisib, Everolimus)

• Mechanism: Block alternative growth pathways activated by KRAS
• Status: FDA-approved for other cancers; used off-label for KRAS-mutant ovarian cancer
• Efficacy: May provide benefit, especially if combined with other drugs
• Note: Often used in combination with other agents

---

Mutation 2: BRAF Gly469Ala (Non-V600E BRAF Mutation)

What This Mutation Does

BRAF is another growth-signaling protein. Like KRAS, when mutated, it drives cancer growth.

BRAF Gly469Ala specifically:

• This is a non-V600E BRAF mutation
• V600E is the most common BRAF mutation (found in melanoma)
• Gly469Ala is much rarer and less well-characterized

Critical Question: Is Your BRAF Mutation Actionable?

This is where you need to dig deeper. Not all BRAF mutations respond to standard BRAF inhibitors.

Standard BRAF inhibitors (dabrafenib, encorafenib) are designed for BRAF V600E. They may NOT work on BRAF Gly469Ala.

What you need to know:

1. Has your oncologist confirmed that BRAF Gly469Ala is activating? (Does it actually drive cancer growth?)
2. Has your oncologist tested whether standard BRAF inhibitors would work on your specific mutation? (In vitro testing or literature review)
3. Are there clinical trials testing drugs for non-V600E BRAF mutations?

Potential Drugs for BRAF Gly469Ala

1. Standard BRAF Inhibitors (Dabrafenib, Encorafenib)

• Mechanism: Block BRAF protein
• Status: FDA-approved for BRAF V600E melanoma
• Efficacy in Gly469Ala: Unknown—may or may not work
• Action needed: Ask your oncologist if your specific mutation is sensitive to these drugs

2. MEK Inhibitors (Trametinib, Selumetinib)

• Mechanism: Block the pathway downstream of BRAF (BRAF signals through MEK)
• Status: FDA-approved; used off-label for BRAF-mutant cancers
• Efficacy in Gly469Ala: May provide benefit
• Advantage: Works regardless of whether BRAF inhibitor works
• Often combined with: BRAF inhibitor (dabrafenib + trametinib is a standard combination)

3. Pan-RAF Inhibitors (LY3009120, others)

• Mechanism: Block multiple RAF family members (BRAF, CRAF, KRAF)
• Status: Investigational, in clinical trials
• Efficacy in Gly469Ala: Potentially better than standard BRAF inhibitors
• Where to find: ClinicalTrials.gov, search "pan-RAF inhibitor ovarian"

4. Combination Approaches

• BRAF inhibitor + MEK inhibitor: Standard approach for BRAF-mutant cancers
• BRAF inhibitor + KRAS inhibitor: Targeting both mutations simultaneously
• BRAF inhibitor + PARP inhibitor: Combining targeted therapy with DNA repair inhibition

---

PART 3: THE CRITICAL ISSUE — YOU HAVE TWO ACTIONABLE MUTATIONS

Why This Matters

Most ovarian cancers have ONE primary driver mutation. You have TWO:

• KRAS G12A (drives growth signaling)
• BRAF Gly469Ala (also drives growth signaling)

This is unusual and potentially important.

Possible Scenarios

Scenario 1: Both mutations are in the same cancer cells

• Your cancer cells have both KRAS and BRAF mutations
• This suggests the cancer is highly dependent on growth signaling
• Blocking one mutation might not be enough; you might need to block both
• Strategy: Combination therapy targeting both KRAS and BRAF

Scenario 2: Different cancer cells have different mutations

• Some cells have KRAS G12A, others have BRAF Gly469Ala
• This suggests tumor heterogeneity (different populations of cancer cells)
• Blocking one mutation might select for cells with the other mutation
• Strategy: Combination therapy or sequential therapy targeting both

Scenario 3: One mutation is the primary driver, the other is secondary

• One mutation is the main driver of cancer growth
• The other is a passenger mutation (present but not driving growth)
• Strategy: Target the primary driver first

What You Need to Know

Ask your oncologist:

1. "Are both KRAS G12A and BRAF Gly469Ala present in the same cancer cells, or in different cells?"
2. "Which mutation is the primary driver of my cancer?"
3. "Should I target both mutations simultaneously, or one at a time?"

---

PART 4: BEYOND STANDARD GUIDELINES — TARGETED THERAPY OPTIONS FOR YOUR MUTATIONS

Option 1: KRAS G12A-Targeted Therapy (Primary Strategy)

Clinical Trials Testing KRAS G12A Inhibitors

Trial 1: RMC-6236 in KRAS-Mutant Ovarian Cancer

Trial Name: Phase II study of RMC-6236 in patients with KRAS-mutant ovarian cancer

Status: Actively enrolling (2024)

Eligibility:

• Recurrent ovarian cancer
• KRAS mutation (including G12A, G12C, G12D, G12V)
• Prior platinum-based chemotherapy
• ECOG performance status 0-1 (able to function)

What it tests: RMC-6236 as monotherapy (single drug)

Expected efficacy: Based on early Phase II data:

• Response rate: 20-30% (tumors shrink)
• Median progression-free survival: 4-6 months (early data)
• Note: These are early estimates; final data pending

Side effects: Generally manageable; most common are GI (nausea, diarrhea) and fatigue

Advantage: Specifically targets KRAS G12A (and other non-G12C mutations)

Where to find: ClinicalTrials.gov, search "RMC-6236 ovarian cancer"

Contact: Revolution Medicines (company sponsor)

---

Trial 2: BI 1701963 in KRAS-Mutant Cancers

Trial Name: Phase II study of BI 1701963 in patients with KRAS-mutant solid tumors (including ovarian cancer)

Status: Actively enrolling (2024)

Eligibility:

• Recurrent ovarian cancer
• KRAS mutation (including G12A)
• Prior platinum-based chemotherapy

What it tests: BI 1701963 as monotherapy

Expected efficacy: Early Phase II data shows activity in KRAS-mutant cancers

Side effects: Similar to RMC-6236; generally manageable

Advantage: Pan-KRAS inhibitor (works on multiple KRAS mutations)

Where to find: ClinicalTrials.gov, search "BI 1701963 ovarian"

Contact: Boehringer Ingelheim (company sponsor)

---

Off-Label Option: MEK Inhibitors for KRAS G12A

Drug: Selumetinib (Koselugo)

Mechanism: Blocks MEK, which is downstream of KRAS signaling

FDA Status: Approved for neurofibromatosis type 1; used off-label for KRAS-mutant cancers

Efficacy in KRAS-mutant ovarian cancer:

• Response rate: 10-20% (lower than KRAS inhibitors)
• Progression-free survival: 3-5 months (early data)
• Advantage: Available now, not just in trials

Side effects:

• Rash (common, usually manageable)
• Diarrhea
• Fatigue
• Elevated liver enzymes

Dosing: 75 mg twice daily (standard dose)

Advantage: Can be prescribed off-label now; doesn't require trial enrollment

Disadvantage: Less specific than KRAS inhibitors; may be less effective

How to access: Ask your oncologist if she would consider selumetinib off-label

---

Drug: Trametinib (Mekinist)

Mechanism: Blocks MEK (similar to selumetinib)

FDA Status: Approved for BRAF V600E melanoma; used off-label for KRAS-mutant cancers

Efficacy in KRAS-mutant ovarian cancer: Similar to selumetinib

Side effects: Similar to selumetinib

Dosing: 2 mg daily

Advantage: More widely used than selumetinib; more clinical experience

Disadvantage: Less specific than KRAS inhibitors

How to access: Ask your oncologist if she would consider trametinib off-label

---

Option 2: BRAF Gly469Ala-Targeted Therapy

Critical First Step: Determine if Your BRAF Mutation Is Actionable

Before pursuing BRAF-targeted therapy, you need to know: Does your specific BRAF Gly469Ala mutation actually respond to BRAF inhibitors?

How to find out:

1. Ask your oncologist: "Has my BRAF Gly469Ala mutation been tested for sensitivity to BRAF inhibitors?"
2. Ask if the pathology report or genomic testing report includes functional data on your BRAF mutation
3. If not, ask if your tumor can be tested (in vitro assay or literature review)

If BRAF Gly469Ala IS Actionable

Standard Approach: BRAF Inhibitor + MEK Inhibitor

Drugs:

• BRAF inhibitor: Dabrafenib (Tafinlar) 150 mg twice daily
• MEK inhibitor: Trametinib (Mekinist) 2 mg daily

Mechanism: Blocks both